We are Prescient. We turn science into value for the biopharma industry.
The science of a molecule is rarely what determines whether a drug will become the market leader; people determine whether the molecule becomes that market leader, by translating the scientific potential into a value proposition that resonates with stakeholders as relevant, differentiated and meaningful.
We help biopharmaceutical clients develop winning strategies for their molecules every single day, giving the molecules in their hands a greater potential for success than the same science in the hands of their competitors.
Prescient BusinessesFocused on you today, tomorrow and beyondIntelligence & InsightShaping your competitive strategyAdvisoryPrecise strategies for your precision medicinesInflexionRxBringing insight to life
We travel the drug development and commercialization journey
No matter where you are on the drug development and commercialization journey, Prescient is there. From early development to launch, from the critical first 12 months on the market to loss of exclusivity, we’re by your side, providing the dynamic insight, expertise, objectivity and creativity required to make aligned decisions, differentiated decisions and valuable decisions.
At Prescient, science is at the core of everything we do. We are experts at maximizing the value of science for your patients, your company and you.
By understanding the potential of your molecules, we can frame your options and make decision making the biggest differentiating factor in your products’ success. We take a forward-looking approach, anticipating the future and helping you prepare for what’s ahead.
Exceptional levels of clinical and commercial strategy expertise led by a team of 20 senior VPs and directors averaging 19 years’ experience in pharma and biotechGet in touch with PrescientStable relationships, with an average tenure at Prescient of more than eight years among the senior teamGet in touch with PrescientA truly global reach delivered from six offices across three continents with more than 20 languages spokenGet in touch with PrescientMore than 150 biopharma strategy experts, of whom more than 80% have advanced degreesGet in touch with Prescient
Learn more about how we turn science into value
Prescient Healthcare Group announced today that Bridgepoint Development Capital, part of Bridgepoint, the international alternative asset management group, has agreed to invest in the business for an undisclosed sum, replacing current investor Baird Capital as the majority shareholder.
Turn your expertise into a valuable career at Prescient
We are looking for people who want to immerse themselves in a passionate community of experts focused on bringing innovative, life-enhancing drugs to patients.
Whether you’re a new graduate, a scientist looking for a change, a seasoned consultant wanting to specialize or an industry professional with an entrepreneurial spirit, at Prescient, you have the opportunity to excel and do work that matters.
Prescient is an exciting and fast-growing biopharma strategy firm backed by private equity. But we are so much more than that—because the work we do is so much bigger than that.